Serum Lactate Dehydrogenase Contributes to Prognostic Assessment in Patients With Oligometastatic Cancer and Brain Involvement

被引:8
作者
Nieder, Carsten [1 ,2 ]
Dalhaug, Astrid [1 ]
Pawinski, Adam [1 ]
机构
[1] Nordland Hosp, Dept Oncol & Palliat Med, N-8092 Bodo, Norway
[2] UiT Arctic Univ Norway, Dept Clin Med, Fac Hlth Sci, Tromso, Norway
来源
IN VIVO | 2019年 / 33卷 / 01期
关键词
Palliative radiotherapy; whole brain radiotherapy; brain metastases; oligometastases; prognostic factors; lactate dehydrogenase; CELL LUNG-CANCER; STEREOTACTIC BODY RADIOTHERAPY; SURVIVAL; DISEASE; RADIOSURGERY; METASTASES; STRATEGIES; THERAPY;
D O I
10.21873/invivo.11464
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: The aim of this study was to analyze the prognostic impact of serum lactate dehydrogenase (LDH) in patients with oligometastatic brain metastases, arbitrarily defined as max. Four brain lesions and 5 metastatic lesions overall. Patients and Methods: This was a retrospective single institution analysis. Overall, 42 patients were identified from a prospectively maintained database. Results: Seventeen patients (40%) had extracranial metastases. Twelve patients (29%) had elevated LDH (>= 255 U/l). Their median survival was significantly shorter than that of patients with normal LDH. Due to an interaction with performance status, this result was separately confirmed in patients with performance status >= 70. Conclusion: Oligometastatic disease is not always correctly diagnosed, because all radiological modalities are limited by certain thresholds for detection of small metastases. We hypothesize that LDH is associated with survival, because this biomarker may reflect the total burden of malignant disease. Future studies should examine whether or not ablative local treatment of oligometastases is warranted in patients with elevated LDH.
引用
收藏
页码:229 / 232
页数:4
相关论文
共 20 条
  • [1] Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up
    Ampil, Federico
    Ellika, Shehanaz
    Nanda, Anil
    Vora, Moiz
    [J]. ANTICANCER RESEARCH, 2017, 37 (09) : 5113 - 5115
  • [2] An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer
    Ashworth, Allison B.
    Senan, Suresh
    Palma, David A.
    Riquet, Marc
    Ahn, Yong Chan
    Ricardi, Umberto
    Congedo, Maria T.
    Gomez, Daniel R.
    Wright, Gavin M.
    Melloni, Giulio
    Milano, Michael T.
    Sole, Claudio V.
    De Pas, Tommaso M.
    Carter, Dennis L.
    Warner, Andrew J.
    Rodrigues, George B.
    [J]. CLINICAL LUNG CANCER, 2014, 15 (05) : 346 - 355
  • [3] Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group
    deSouza, Nandita M.
    Liu, Yan
    Chiti, Arturo
    Oprea-Lager, Daniela
    Gebhart, Geraldine
    Van Beers, Bernard E.
    Herrmann, Ken
    Lecouvet, Frederic E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 91 : 153 - 163
  • [4] Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
    Gomez, Daniel R.
    Blumenschein, George R., Jr.
    Lee, J. Jack
    Hernandez, Mike
    Ye, Rong
    Camidge, D. Ross
    Doebele, Robert C.
    Skoulidis, Ferdinandos
    Gaspar, Laurie E.
    Gibbons, Don L.
    Karam, Jose A.
    Kavanagh, Brian D.
    Tang, Chad
    Komaki, Ritsuko
    Louie, Alexander V.
    Palma, David A.
    Tsao, Anne S.
    Sepesi, Boris
    William, William N.
    Zhang, Jianjun
    Shi, Qiuling
    Wang, Xin Shelley
    Swisher, Stephen G.
    Heymach, John V.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1672 - 1682
  • [5] Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
    Lecouvet, Frederic E.
    Oprea-Lager, Daniela E.
    Liu, Yan
    Ost, Piet
    Bidaut, Luc
    Collette, Laurence
    Deroose, Christophe M.
    Goffin, Karolien
    Herrmann, Ken
    Hoekstra, Otto S.
    Kramer, Gem
    Lievens, Yolande
    Lopci, Egesta
    Pasquier, David
    Petersen, Lars J.
    Talbot, Jean-Noel
    Zacho, Helle
    Tombal, Bertrand
    desouza, Nandita M.
    [J]. LANCET ONCOLOGY, 2018, 19 (10) : E534 - E545
  • [6] Predicting prognosis of short survival time after palliative whole-brain radiotherapy
    Miyazawa, Kazunari
    Shikama, Naoto
    Okazaki, Shohei
    Koyama, Tadaaki
    Takahashi, Takao
    Kato, Shingo
    [J]. JOURNAL OF RADIATION RESEARCH, 2018, 59 (01) : 43 - 49
  • [7] The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases
    Nieder, C.
    Hintz, M.
    Oehlke, O.
    Bilger, A.
    Grosu, A. L.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (09) : 1141 - 1146
  • [8] Prognostic Models Predicting Survival of Patients with Brain Metastases: Integration of Lactate Dehydrogenase, Albumin and Extracranial Organ Involvement
    Nieder, C.
    Marienhagen, K.
    Dalhaug, A.
    Aandahl, G.
    Haukland, E.
    Pawinski, A.
    [J]. CLINICAL ONCOLOGY, 2014, 26 (08) : 447 - 452
  • [9] Survival After Palliative Radiotherapy in Patients with Breast Cancer and Bone-only Metastases
    Nieder, Carsten
    Dalhaug, Astrid
    Pawinski, Adam
    Mannsaker, Bard
    Haukland, Ellinor
    [J]. IN VIVO, 2016, 30 (06): : 879 - 883
  • [10] Oligometastatic Non-Small Cell Lung Cancer: A Significant Entity outside of Specialized Cancer Centers?
    Nieder, Carsten
    Tollali, Terje
    Reigstad, Anne
    Pawinski, Adam
    Haukland, Ellinor
    Dalhaug, Astrid
    [J]. MEDICAL PRINCIPLES AND PRACTICE, 2014, 23 (06) : 526 - 531